Algo version: 0.98b
Vertex Pharmaceuticals is listed at the XETRA Exchange
Vertex Pharmaceuticals [VX1.DE]
XETRA Sector: Biotechnology Industry:Biotechnology

Is Vertex Pharmaceuticals stock a buy?

What Is The Conclusion?

Right now our advanced algorithms say:

Do the analyst corps agree?

Interesting Questions and Easy Answers!

We cannot find any recorded dividends paid in our systems.

Sorry, we do not have any analyst data for this ticker

We cannot find data for Vertex Pharmaceuticals 10 years ago, but if you had invested on Monday 9th of September 2019 when the price was €137.03, you would have made a profit of €281.87 per share or 205.70%

No, the average daily trading liquidity for Vertex Pharmaceuticals is €530 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.

Vertex Pharmaceuticals has no real debt, which is good in periods of high inflation. With a high cash flow to debt ratio of 5.47, the company's ability to pay off the debt is good. Vertex Pharmaceuticals has a very good net profit margin of 39.46% and should have very high tolerances against inflation.

We have calculated the inflation risk for Vertex Pharmaceuticals to be low [0 of 1]

US inflation for July 2024 was 0.15%. Over the last 12 months, the US inflation is 2.92%. The 10-year treasury yield that indicates the future interest level is currently 3.72 and is down -0.95 over the last 30 days.